PRIVATE EQUITY INTERNATIONAL
Mellon backs early-stage genetics fund
IRegent, Jim Mellon’s Hong Kong investment group, provides initial backing for a new genetic medicine fund.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
- Database
- LP search
- GP search
- Fund search
- Commitments
- Investment Consultant search
- Placement Agent search
- Law Firm search
- Live Fundraising Chart
- Benchmarks
- Institution Profiles Index
- Private Equity Data
- Investor Calendar
- Update your database profile
- Law firm data submission
- Database key terms and methodology
- Fund performance methodology
- Quick Search
- Meet the LP Series
- PEI 300: The World’s Largest Private Equity Firms
- Side Letter
- Friday Letters
- Guest Comment
- Private Equity Investor Intentions and Preferences
- Private Take
- Private Wealth
- The Democratisation of Private Equity
- Magazine
- LP Perspectives 2026
- Top Private Equity Placement Agents
- Secondaries
- Performance
- Latest News & Analysis
- Rankings & Reports
- Events
- Bookstore
- Podcasts
